About
About Nymox Pharmaceutical Corporation
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, The Bahamas.
Visit company website
5 years, 5 months ago
Nymox Pharmaceutical Corporation is currently in a long term downtrend where the price is trading 31.4% below its 200 day moving average.
From a valuation standpoint, the stock is 2338.5% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 32029.8.
Nymox Pharmaceutical Corporation's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has increased by 24.6% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 6.5% to $-2M since the same quarter in the previous year.
Based on the above factors, Nymox Pharmaceutical Corporation gets an overall score of 2/5.